Portal de Periódicos da CAPES

Molecular aspects of tumor cell invasion and metastasis

1993; Wiley; Volume: 71; Issue: 4 Linguagem: Inglês

10.1002/1097-0142(19930215)71

1097-0142

Sadie Aznavoorian, Anne N. Murphy, William G. Stetler‐Stevenson, Lance A. Liotta,

Ubiquitin and proteasome pathways

CancerVolume 71, Issue 4 p. 1368-1383 Review ArticleFree Access Molecular aspects of tumor cell invasion and metastasis Sadie Aznavoorian Ph.D., Corresponding Author Sadie Aznavoorian Ph.D. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MarylandLaboratory of Pathology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892===Search for more papers by this authorAnne N. Murphy Ph.D., Anne N. Murphy Ph.D. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MarylandSearch for more papers by this authorWilliam G. Stetler-Stevenson M.D., Ph.D., William G. Stetler-Stevenson M.D., Ph.D. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MarylandSearch for more papers by this authorLance A. Liotta M.D., Ph.D, Lance A. Liotta M.D., Ph.D Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MarylandSearch for more papers by this author Sadie Aznavoorian Ph.D., Corresponding Author Sadie Aznavoorian Ph.D. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MarylandLaboratory of Pathology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892===Search for more papers by this authorAnne N. Murphy Ph.D., Anne N. Murphy Ph.D. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MarylandSearch for more papers by this authorWilliam G. Stetler-Stevenson M.D., Ph.D., William G. Stetler-Stevenson M.D., Ph.D. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MarylandSearch for more papers by this authorLance A. Liotta M.D., Ph.D, Lance A. Liotta M.D., Ph.D Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MarylandSearch for more papers by this author First published: 15 February 1993 https://doi.org/10.1002/1097-0142(19930215)71:4 3.0.CO;2-LCitations: 312AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Fidler IJ, Hart IR. Biologic diversity in metastatic neoplasms: origins and implications. Science 1982; 217: 998–1001. 2 Schirrmacher V. Experimental approaches, theoretical concepts, and impacts for treatment strategies. Adv Cancer Res 1985; 43: 1–32. 3 Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49: 636. 4 Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–6. 5 Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442–7. 6 Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58–61. 7 Liotta L, Kleinerman J, Saidel G. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974; 34: 997–1004. 8 Furcht LT. Critical factor controlling angiogenesis: cell products, cell matrix, and growth factors [editorial]. Lab Invest 1986; 55: 505–9. 9 Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Sem Cancer Biol 1990; 1: 99–106. 10 Lola PK, Graham CH. Mechanisms of trophoblast invasiveness and their control: the role of proteases and protease inhibitors. Cancer Metastasis Rev 1990; 9: 369–80. 11 Alexander CM, Werb Z. Extracellular matrix degradation. In: ED Hay, editor. Cell biology of the extracellular matrix. 2nd ed. New York: Plenum Press, 1991: 255–302. 12 Hynes RO. Integrins: a family of cell surface receptors. Cell 1987; 48: 549. 13 Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986; 233: 467. 14 Rao C, Castronovo V, Schmitt MC, Wewer U, Claysmith A, Liotta LA, et al. Evidence for a precursor of the high-affinity metastasis associated murine laminin receptor. Biochemistry 1989; 28: 7476–86. 15 Aznavoorian S, Stracke ML, Krutzsch H, et al. Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol 1990; 110: 1427. 16 Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11–25. 17 Yamada KM, Kennedy DW. Dualistic nature of adhesive protein function: fibronectin and its biologically active peptide fragments can autoinhibit fibronectin function. J Cell Biol 1984; 99: 29–36. 18 Horwitz A, Duggan C, Buck C, Beckerle MC, Burridge K. Interaction of plasmafibronectin receptor with talin: a transmembrane linkage. Nature 1986; 320: 531–3. 19 Barsky SH, Rao CN, Williams JE, Liotta LA. Laminin molecular domains which alter metastasis in a murine model. J Clin Invest 1984; 74: 843–8. 20 Gehlsen KR, Argraves WS, Pierschbacher MD, Ruoslahti E. Inhibition of in vitro cell invasion by Arg-Gly-Asp-containing peptides. J Cell Biol 1988; 106: 925–30. 21 Humphries MJ, Yamada KM, Olden K. Investigation of the biological effects of anti-cell adhesion synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells. J Clin Invest 1988; 81: 782–90. 22 Saiki I, Murata J, Ida J, Nishi N, Sigimura K, Azuma I. The inhibition of murine lung metastasis by synthetic polypeptides [poly (arg-gly-asp) and poly (tyr-ile-gly-ser-arg)] with a core sequence of cell adhesion molecules. Br J Cancer 1989; 59: 194–7. 23 Plantefaber LC, Hynes RO. Changes in integrin receptors on oncogenically transformed cells. Cell 1989; 56: 281–90. 24 Albelda SM, Matte SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, et al. Integrin distribution in malignant melanoma: association of the β3 subunit with tumor progress. Cancer Res 1990; 50: 6757–64. 25 Gehlsen KR, Davis GE, Sriramarao P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin Exp Metastasis 1992; 10: 111–20. 26 Chen W-T, Wang J, Hasegawa T, Yamada SS, Yamada KM. Regulation of fibronectin receptor distribution by transformation, exogenous fibronectin, and synthetic peptides. J Cell Biol 1986; 103: 1649–61. 27 Roman J, LaChance RM, Brockelmann TJ, Kennedy CJR, Wayner EA, Carter WG, et al. The fibronectin receptor is organized by extracellular matrix fibronectin: implications for oncogenic transformation and for recognition of fibronectin matrices. J Cell Biol 1989; 108: 2529–43. 28 Giancotti FG, Ruoslahti E. Elevated levels of the α5β1 fibronectin receptor suppress the transformed phenotype of chinese hamster ovary cells. Cell 1990; 60: 849–59. 29 Symington BE. Fibronectin receptor overexpression and loss of transformed phenotype in a stable variant of the K562 cell line. Cell Regul 1990; 1: 637–48. 30 Schreiner C, Fisher M, Hussein S, Juliano RL. Increased tumorigenicity of fibronectin receptor deficient chinese hamster ovary cell variants. Cancer Res 1991; 51: 1738–40. 31 Yamada KM. Adhesive recognition sequences. J Biol Chem 1991; 266: 12809–12. 32 Seftor REB, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E, et al. Role of the αvβ3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992; 89: 1557–61. 33 Wewer UM, Liotta LA, Jaye M, Ricca GA, Drohan WN, Claysmith AP, et al. Altered levels of laminin receptor mRNA in various human carcinoma cells that have different abilities to bind laminin. Proc Natl Acad Sci USA 1986; 83: 7137. 34 Rao CN, Margulies I, Tralka TS, Terranova VP, Madri JA, Liotta LA. Isolation of a subunit of laminin and its role in molecular structure and tumor cell attachment. J Biol Chem 1982; 257: 9740–4. 35 Wewer UM, Taraboletti G, Sobel ME, Albrechtsen R, Liotta LA. Role of laminin receptor in tumor cell migration. Cancer Res 1987; 47: 5691–8. 36 Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem 1990; 59: 237–52. 37 Behrens J, Marcel MM, VanRoy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989; 108: 2435–47. 38 Uleminckx K, Vakact L Jr., Marcel M, Fiers W, VanRoy FV. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66: 107–19. 39 Wang BS, McLouglin GA, Richie JP, Mannick JA. Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines. Cancer Res 1980; 40: 288–92. 40 Reich R, Thompson E, Iwamoto Y, Martin GR, Deason JR, Fuller GC, et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988; 48: 3307–12. 41 Axelrod JH, Reich R, Mishkin R. Expression of human recombinant plasminogen activators enhance invasion and experimental metastasis of Ha-ras transformed NIH 3T3 cells. Mol Cell Biol 1989; 9: 2133–41. 42 Rochefort H, Capony F, Garcia M. Cathepsin D: a protease involved in breast cancer metastasis. Cancer Metastasis Rev 1990; 9: 321–31. 43 Recklies AD, Poole AR, Mort JS. A cysteine proteinase secreted from human breast tumors is immunologically related to cathepsin B. Biochem J 1982; 207: 633–6. 44 Sloane BR, Honn KV. Cysteine proteinases and metastasis. Cancer Metastasis Rev 1984; 3: 249–63. 45 Liotta LA, Abe S, Robey P, Martin G. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc Natl Acad Sci USA 1979; 76: 2268–72. 46 Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67–8. 47 Ostrowski LE, Rinch J, Kreig P, Matrisian L. Expression pattern of a gene for a secreted metalloproteinase during late stages of tumor progression. Molecular Carcinogenesis 1988; 1: 13–9. 48 Templeton NS, Brown PD, Levy AT, Margulies IMK, Liotta LA, Stetler-Stevenson WG. Cloning and characterization of human tumor cell interstitial collagenase. Cancer Res 1990; 50: 5431–7. 49 Nakajima M, Welch D, Belloni PN, Nicolson GL. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 1987; 47: 4869–76. 50 Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst 1991; 82: 1890–8. 51 Thorgeirsson UP, Liotta LA, Kalebic T, Margulies I, Thomas K, Rios-Candelore M, et al. Effect of natural protease inhibitors and a chemoattractant on tumor cell invasion in vitro. J Natl Cancer Inst 1982; 69: 1049–54. 52 Mignatti P, Robbins E, Rifkin D. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 1986; 47: 487–98. 53 Wang M, Stearns ME. Blocking of collagenase secretion by estamustine during in vitro tumor cell invasion. Cancer Res 1988; 48: 6262–71. 54 Dano K, Andreasen PA, Grondahl-Hansen J, et al. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139–266. 55 Sappino A-P, Busso N, Belin D, Vassali J-D. Increase of urokinase type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 1987; 47: 4043–6. 56 Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611–9. 57 Esheicher A, Wohlwend A, Belin D, Vassalli JD. Characterization of the cellular binding site for the urokinase type plasminogen activator. J Biol Chem 1989; 264: 1180–9. 58 Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327–36. 59 Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends in Genetics 1990; 6: 121–5. 60 Hasty KA, Pourmotabbed TF, Goldberg GI, Thompson JP, Spinella DG, Stevens RM, et al. Human neutrophil collagenase. J Biol Chem 1990; 265: 11421–4. 61 Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699–704. 62 Matrisian L, Bowden T. Stromelysin/transin and tumor progression. Semin Cancer Biol 1990; 1: 107–115. 63 McDonnell S, Naure M, Coffey RJ, Jr., Matrisian LM. Expression and localization of the matrix metalloproteinase Pump-1 (MMP-7) in human gastric and colon carcinomas. Molecular Carcinogenesis 1991; 4: 527–33. 64 Polette M, Clavel C, Muller D, Abecassis J, Binninger I, Birembaut P. Detection of mRNAs encoding collagenase I and stromelysin 2 in carcinomas of the head and neck by in situ hybridization. Invasion Metastasis 1991; 11: 76–83. 65 Fessler L, Duncan K, Tryggvason K. Identification of the procollagen IV cleavage products produced by a specific tumor collagenase. J Biol Chem 1984; 259: 9783–9. 66 Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, et al. H-ras oncogene transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement membrane collagen. J Biol Chem 1988; 263: 6579–87. 67 Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI. SV40-transformed human lung fibroblasts secrete a 92-kDa type-IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989; 264: 17213–21. 68 Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2): a new member of the metalloproteinase inhibitor family. J Biol Chem 1989; 264: 17374–8. 69 Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He C. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci USA 1989; 86: 8207–11. 70 Declerck YA, Yean TD, Ratzkin BJ, Lu HS, Langley KE. Purification and characterization of two related but distinct metalloproteinase inhibitors secreted by bovine aortic endothelial cells. J Biol Chem 1989; 264: 17445–53. 71 Murphy G, Cawston T, Reynolds J. An inhibitor of collagenase from human amniotic fluid: purification, characterization, and action on metalloproteinases. Biochem J 1981; 195: 167–70. 72 Stricklin GP, Welgus HG. Human skin fibroblast collagenase inhibitor: purification and biochemical characterization. J Biol Chem 1983; 258: 12252–8. 73 Carmichael DF, Sommer A, Thomson R, Anderson DC, Smith CG, Welgus HG, et al. Primary structure and cDNA cloning of human fibroblast collagenase inhibitor. Proc Natl Acad Sci USA 1986; 83: 2407–11. 74 Stetler-Stevenson WG, Brown PD, Onisto M, Levy A, Liotta LA. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990; 265: 13933–8. 75 Boone TC, Johnson MJ, DeClerck YA, Langley KE. cDNA cloning and expression of a metalloproteinase inhibitor related to tissue inhibitor of metalloproteinase. Proc Natl Acad Sci USA 1990; 82: 2800–4. 76 Howard EW, Bullen EC, Banda MJ. Preferential inhibition of 72 kDa and 92 kDa gelatinases by TIMP-2. J Biol Chem 1991; 266: 13070–5. 77 Nakajima M, Lotan D, Baig MM, Carralero RM, Wood WR, Hendrix MJC, et al. Inhibition by retinoic acid of type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells. Cancer Res 1989; 49: 1698–706. 78 Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant S, Liotta LA. Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst 1985; 75: 99–108. 79 Muschel RJ, Williams JE, Lowy DR, Liotta LA. Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell. Am J Pathol 1985; 121: 1–8. 80 Garbisa S, Pozzatti R, Muschel R, Saffiotti U, Ballin M, Goldfarb RH, et al. Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-Ela. Cancer Res 1987; 47: 1523–8. 81 Bonfil DR, Reddel RR, Ura H, Reich R, Fridman R, Harris CC, et al. Invasive and metastatic potential of a v-Ha-ras-transformed human bronchial epithelial cell line. J Natl Cancer Inst 1989; 81: 587–94. 82 Ura H, Bonfil RD, Reich R, Reddel R, Pfeifer A, Harris CC, Klein AJP. Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells. Cancer Res 1989; 49: 4615–21. 83 D'Errico A, Garbisa S, Liotta LA, Castronovo V, Stetler-Stevenson WG, Griogioni WG. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Pathol 1991; 4: 239–46. 84 Levy A, Cioce V, Sobel ME, Garbisa S, Griogioni WF, Liotta LA, et al. Increased expression of the 72 kDa type IV collagenase in human colonic adenocarcinoma. Cancer Res 1991; 51: 439–44. 85 Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta L, Wright PA, Jeffrey RE, et al. Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389–96. 86 Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 1990; 136: 585–92. 87 Campo E, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA, Merino MJ. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Pathol 1992; 16: 500–7. 88 Campo E, Merino MJ, Liotta LA, Neumann R, Stetler-Stevenson WG. Distribution of the 72 kDa type IV collogenase in non-neoplastic and neoplastic thyroid tissue. Hum Pathol. In press. 89 Ohori NP, Yousem SA, Griffin J, Stanis K, Stetler-Stevenson WG, Colby TV, et al. Comparison of extracellular matrix antigens in subtypes of bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma: an immunohistochemical study. Am J Surg Pathol 1992; 16: 657–86. 90 Pyke C, Ralfkiaer E, Huhtala P, Hurskainein T, Danø K, Tryggvason K. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 1992; 52: 1336–41. 91 Schultz RM, Silberman S, Persky B, Bajowski AS, Carmichael DF. Inhibition by recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16–F10 melanoma cells. Cancer Res 1988; 48: 5539–45. 92 Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 1990; 82: 589–95. 93 Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, et al. Antisense RNA-induced reduction in metalloproteinase inhibitor causes mouse 3T3 cells to become tumorigenic. Science 1989; 243: 947–50. 94 DeClerck YA, Yean T-D, Chan D, Shimada H, Langley KE. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res 1991; 51: 2151–7. 95 Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991; 83: 775–9. 96 DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52: 701–8. 97 Mignatti P, Tsuboi R, Robbins E, Rifkin D. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989; 108: 671–82. 98 Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990; 248: 1408–10. 99 Moses MA, Langer R. A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem 1991; 47: 230–5. 100 Takigawa M, Nishida Y, Suzuki F, Kishi J, Yamashita K, Hayakawa T. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem Biophys Res Commun 1990; 171: 1264–71. 101 Brown PD, Levy AT, Margulies IMK, Liotta LA, Stetler-Stevenson WG. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 1990; 50: 6184–91. 102 Brinckerhoff CE, Plucinska IM, Sheldon LA, O'Connor GT. Half-life of synovial cell collagenase mRNA is modulated by phorbol myristate acetate but not by all-trans-retinoic acid or dexamethasone. Biochemistry 1986; 25: 6378–84. 103 Kreig P, Finch J, Furstenberger G, Melber K, Matrisian LM, Bowden GT. Tumor promoters induce a transient expression of tumor-associated genes in both basal and differentiated cells of the mouse epidermis. Carcinogenesis 1988; 9: 95–100. 104 Angel P, Baumann I, Stein B, Delius H, Rahmsdorf HJ, Herrlich P. 12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5′-flanking region. Mol Cell Biol 1987; 7: 2256–66. 105 Matrisian LM, Leroy P, Ruhlmann C, Gesnel M-C, Breathnach R. Isolation of the oncogene and epidermal growth factor-induced transin gene: Complex control in rat fibroblasts. Mol Cell Biol 1986; 6: 1679–86. 106 Huhlala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem 1990; 265: 11077–82. 107 Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJP, Angel P, Heath JK. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987; 6: 1899–1904. 108 Kerr LD, Miller DB, Matrisian LM. TGF-β1 inhibition of transin/ stromelysin gene expression is mediated through a fos binding sequence. Cell 1990; 61: 267–78. 109 Overall CM, Wrana JL, Sodek J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloproteinase inhibitor expression in human fibroblasts by transforming growth factor-β. J Biol Chem 1989; 264: 1860–9. 110 MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinase-1 in rheumatoid human synovial fibroblasts. J Biol Chem 1990; 265: 17: 238–45. 111 Vallee BL, Auld DS. Zinc coordination, function, and structure of zinc enzymes and other proteins. Biochemistry 1990; 29: 5647–59. 112 Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990; 87: 5578–82. 113 Stetler-Stevenson WG, Talano J-A, Gallager ME, Krutzsch HC, Liotta LA. Inhibition of human type IV collagenase by a highly conserved peptide sequence derived from its prosegment. Am J Med Sci 1991; 302: 163–70. 114 Stetler-Stevenson WG, Krutzsch HC, Wacher MP, Margulies IMK, Liotta LA. The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation. J Biol Chem 1989; 264: 1353–6. 115 Muller D, Quantin B, Gesnel M-C, Millon-Collard R, Abecassis J, Breathnach R. The collagenase gene family in humans consists of at least four members. Biochem J 1988; 253: 187–92. 116 Melchiori A, Albini A, Ray JM, Stetler-Stevenson WG. Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment. Cancer Res 1992; 52: 2353–6. 117 Ho C, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989; 86: 2632–6. 118 Suziki K, Enghild JJ, Morodarni T, Salvesen G, Nagase H. Mechanism of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry 1990; 29: 10261–70. 119 Briurckerhoff CE, Suzuki K, Mitchell TI, Dram F, Coon CI, Palmiter RD, et al. Rabbit procollagenase synthesized and secreted by a high-yield mammalian expression vector requires stromelysin (matrix metalloproteinase-3) for maximal activation. J Biol Chem 1990; 265: 22266–9. 120 Overall CM, Sodek J. Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. J Biol Chem 1990; 265: 21141–51. 121 Brown PD, Kleiner D, Unsworth E, Stetler-Stevenson WG. Cellular activation mechanism of the 72 kDa type IV collagenase. Kidney Int. In press. 122 Weinberg WC, Brown PD, Stetler-Stevenson WG, Yuspa SH. Growth factors specifically alter hair follicle cell proliferation and collagenolytic activity alone or in combination. Differentiation 1990; 45: 163–78. 123 Apodaca G, Rutka JT, Bouhana K, Berens ME, Giblin JR, Rosenblum ML, et al. Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 1990; 50: 2322–9. 124 Rifas L, Halstead LR, Peck WA, Avioli LV, Welgus HG. Human osteoblasts in vitro secrete tissue inhibitor of metalloproteinases and gelatinase but not interstitial collagenase as major cellular products. J Clin Invest 1990; 84: 686–94. 125 Stetler-Stevenson WG, Liotta LA, Seldin MF. Linkage analysis demonstrates that the Timp-2 locus is on mouse chromosome 11. Genomics 1992; 14: 828–9. 126 Enterline HT, Coman DR. The amoeboid motility of human and animal neoplastic cells. Cancer 1950; 3: 1033–8. 127 Coman DR. Mechanisms responsible for the origin and distribution of blood-borne tumor metastases: a review. Cancer Res 1953; 13: 397–404. 128 Wood S. Pathogenesis of metastasis formation observed in vivo in the rabbit ear chamber. Arch Pathol 1958; 66: 550–68. 129 Hosaka S, Suzuki M, Goto M, Sato H. Motility of rat ascites hepatoma cells, with reference to malignant characteristics in cancer metastasis. Gann 1978; 69: 273–6. 130 Raz A, Ben-Ze'ev A. Cell-contact and -architecture of malignant cells and their relationship to metastasis. Cancer Met Rev 1987; 6: 3–21. 131 Mohler JL, Partin AW, Coffey DS. Prediction of metastatic potential by a new grading system of cell motility: validation in the Dunning R-3327 prostatic adenocarcinoma model. J Urol 1987; 138: 168–70. 132 Rosen EM, Meromsky L, Setter E, Vinter DW, Goldberg ID. Purified scatter factor stimulates epithelial and vascular endothelial cell migration. Proc Soc Exp Biol Med 1990; 195: 34–43. 133 Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol 1990; 111: 2097–108. 134 Kahan BW, Kramp DC. Nerve growth factor stimulation of mouse embryonal cell migration. Cancer Res 1987; 47: 6324–8. 135 Stracke ML, Kohn EC, Azn